Doxycycline hyclate - Aqua Pharmaceuticals

Drug Profile

Doxycycline hyclate - Aqua Pharmaceuticals

Alternative Names: ACTICLATE; ACTICLATE CAP; AQ101; Doxycycline hyclate USP; Monodox

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Aqua Pharmaceuticals
  • Class Antibacterials; Collagenases; Skin disorder therapies; Tetracyclines
  • Mechanism of Action Protein 30S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acne; Anthrax; Bacterial infections; Borrelia infections; Brucellosis; Campylobacter infections; Chancroid; Chlamydial infections; Cholera; Clostridium infections; Escherichia coli infections; Fusobacterium infections; Gonorrhoea; Gram-negative infections; Gram-positive infections; Haemophilus infections; Klebsiella infections; Listeria infections; Malaria; Plague; Pneumonia; Rickettsia infections; Shigella infections; Urethritis
  • Registered Amoebiasis

Most Recent Events

  • 26 Apr 2016 Registered for Anthrax, Borrelia infections, Brucellosis, Campylobacter infections, Chancroid, Chlamydial infections, Cholera, Escherichia coli infections, Gonorrhoea, Haemophilus infections, Klebsiella infections, Plague, Pneumonia, Rickettsia infections, Shigella infections and Urethritis, Clostridium infections (treatment-experienced), Listeria infections (treatment-experienced) and Malaria (treatment-experienced), Acne (adjunctive treatment), Gram-positive infections, Gram-negative infections and Bacterial infections in USA (PO, Capsule)
  • 31 Aug 2014 Launched for severe Acne (Adjunctive treatment) in USA (PO) - First Global Launch
  • 28 Jul 2014 Registered for Acne (adjunctive treatment) in USA (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top